Canadian clinical-stage biopharmaceutical company BioVaxys Technology Corp (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) announced on Thursday the appointment of Brittany Davison, CPA, CA as its new business advisor.
Davison, a chartered professional accountant, is the owner of Davison CPA Consulting Inc of Halifax, Nova Scotia. She previously served as chief accounting officer and acting chief financial officer at IMV Inc and as audit senior with Grant Thornton LLP.
Kenneth Kovan, BioVaxys president & chief operating officer, said: "We are delighted to have engaged Brittany who is a significant addition to our team where she will assist with further knowledge transfer associated with the former IMV Inc assets, support investor relations, business development targeting and outreach, and facilitate sources of private funding, government funding and Scientific Research and Experimental Development (SR&ED) tax incentives."
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA